Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Key value for chemical safety assessment

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion
Endpoint conclusion:
no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Oral administration of FAT 41’029/A to Wistar rats at doses of 50, 200 and 1000 mg/kg/day, for 28 days resulted in no deaths, no test article-related clinical signs (following daily and weekly observation), no effects upon the parameters of the functional observation battery (including grip strength), no changes in body weight and food consumption, and no effects upon hematology or clinical biochemistry parameters, or organ weights. No test article-related macroscopic or microscopic changes were evident at necropsy.

Test article-related changes included slightly decreased locomotor activity at 1000 mg/kg/day, only.

Based on the results of this study, 200 mg/kg body weight/day was established as the no-observed-effect-level (NOEL) and 1000 mg/kg body weight/day as the no-observed-adverse-effect-level (NOAEL).

Justification for classification or non-classification

The test substance shall not be classified in accordance with CLP (Regulation EC No.1272/2008).